Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment options

Testing early for COVID-19 can help determine the proper course of treatment.This collaboration helpspatients access critical resources and locate information about testing, available treatment options, high-risk factors that increase the chance of progressing to severe COVID-19, and ways to seek timely care.The Pilot ® COVID-19 At-Home Test will now include a QR code that directs individuals tocovid19knowmore.com, a Pfizer website, to learn more about testing and treatment options.Basel, 14 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has entered into a U.S. focused collaboration with Pfizer to drive awareness and educate on the importance of timely COVID-19 testing, available treatment options, symptoms and the high-risk factors that can increase the chance of progressing to severe illness.According to the Centers for Disease Control and Prevention, nearly 9 out of 10 adults struggle to understand and use personal and public health information because it contains unfamiliar or complex terms. This collaboration aims to simplify and improve access to health information related to COVID-19. Oncovid19knowmore.com, a Pfizer website, individuals can learn why early testing is important at symptom onset, which health conditions increase the risk of progressing to severe COVID-19 and what treatment options are available.Individuals who test positive, and are age 50 or older or have certain medical conditions - such as chronic lung disease, heart disease or...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news